Spiro compounds as inhibitors of KRAS

A compound of Formula II:

• or a pharmaceutically acceptable salt thereof, wherein:
• Y is NR5N or C═O;
• W is C═O, or C(R8)2;
• Z is O, NR9N, or a bond;
• R1 is selected from H, D, C1-6 alkyl, halo, and CN;
• R2 is selected from H, C1-6 alkyl, C1-6 haloalkyl, and halo;
• wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R20;
• Cy is selected from C6-10 aryl and 5-10 membered heteroaryl;
• wherein the 5-10 membered heteroaryl each has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;
• wherein the N and S are optionally oxidized;
• wherein a ring-forming carbon atom of 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group;
• and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R10;
• R4 is selected from H, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and ORa3;
• wherein said C3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R30;
• R5N is selected from H and C1-6 alkyl;
• wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R50;
• R8 is H;
• ring A is selected from C3-6 cycloalkyl and 4-7 membered heterocycloalkyl;
• wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;
• wherein the N and S are optionally oxidized;
• wherein a ring-forming carbon atom of 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group;
• n is 0, 1 or 2;
• each R6 is independently selected from C(O)Rb6 and C(O)ORa6;
• R7 is halo;
• R9N is H;
• each R10 is independently selected from C1-6 alkyl, halo, and ORa10;
• each R20 is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, and CN;
• wherein said C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, or 3 substituents independently selected from R21;
• each R21 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, D, and CN;
• each R30 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, ORa30, and NRc30Rd30;
• wherein said C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, or 3 substituents independently selected from R31;
• each R31 is C1-6 alkyl;
• each R50 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, D, CN, ORa50, C(O)Rb50, C(O)NRc50Rd50, C(O)ORa50, NRc50Rd50, and NRc50C(O)Rb50;
• Ra3 is C1-6 alkyl optionally substituted with 1, 2, or 3 substituents independently selected from R30;
• each Ra6 and Rb6 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl;
• Ra10 is selected from H, C1-6 alkyl, and C1-6 haloalkyl;
• each Ra30, Rc30 and Rd30 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
• wherein said C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, or 3 substituents independently selected from R31;
• or any Rc30 and Rd30 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R31;
• and
• each Ra50, Rb50, Rc50 and Rd50, is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl.